GLP-1 Drugs Show Promise for Pain Management and Opioid Addiction A new class of diabetes and weight-loss drugs is drawing attention from researchers, and the early data on opioid addiction may be the most compelling signal yet
Elsaid: The ESSENCE trial showed that semaglutide improves liver histology in fibrotic MASH, which is why the FDA approved it for that use
The largest longitudinal study on multi-year supplementation remains limited
y cng l cng ngh ph bin ti chu u , c nhiu chuyn gia da liu khuyn dng cho ngi mun lm sng da an ton, bn vng
STEP-HFpEF was a randomised, controlled trial designed to find out whether semaglutide for 52 weeks could improve heart failure symptoms and physical function in obese, non-diabetic patients with heart failure with preserved ejection fraction (HFpEF)
This finding suggests that impurities disrupting the tolerogenic epitope could contribute to immunogenicity in clinical use